Martin McGlynn
Business Strategy
As we pioneer the translation of our groundbreaking science to breakthrough medicine, we are developing unique core competencies and building a broad intellectual property and technology portfolio designed to create significant value for our stockholders.
We will achieve our Mission by building a world-class, sustainable stem cell-based enterprise that capitalizes on opportunities across multiple markets. Our primary focus is to apply our leadership in stem cell science to the discovery, development and commercialization of innovative therapeutics to treat a broad array of diseases and disorders. Concurrently, we are leveraging our resources to profit in the near-term from the commercialization of tools and technologies for use in stem cell-based research and drug discovery. This strategy balances and diversifies our business prospects and positions us to minimize our capital requirements as we pursue our long-term goals.